Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)

Bu Hong; Fan Ying; Fan Zhaoqing; Hu Xichun; Li Man; Li Qiao; Liao Ning; Luo Ting; Nie Jianyun; Pan Yueyin; Qi Xiaowei; Shao Zhimin; Song Guohong; Sun Tao; Teng Yue-e; Tong Zhongsheng; Wang Jiayu; Wang Shusen; Wang Xue; Wang Yongsheng; Wang Zhonghua; Xu Binghe; Xu Ling; Xue Yan; Yang Wentao; Yao Herui; Ying Jianming; Yuan Peng; Zhang Jian; Zhang Qingyuan; Zhang Yongqiang; Zhao Jiuda

doi:10.1016/j.jncc.2023.09.002

Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)

Bu Hong
, Fan Ying
, Fan Zhaoqing
, Hu Xichun
, Li Man
, Li Qiao
, Liao Ning
, Luo Ting
, Nie Jianyun
, Pan Yueyin
, Qi Xiaowei
, Shao Zhimin
, Song Guohong
, Sun Tao
, Teng Yue-e
, Tong Zhongsheng
, Wang Jiayu
, Wang Shusen
, Wang Xue
, Wang Yongsheng

Wang Zhonghua, Xu Binghe, Xu Ling, Xue Yan, Yang Wentao, Yao Herui, Ying Jianming, Yuan Peng, Zhang Jian, Zhang Qingyuan, Zhang Yongqiang, Zhao Jiuda

Health Science Center

Sichuan University
Chinese Academy of Medical Sciences
Peking University
Fudan University
Dalian Medical University
Guangdong Academy of Medical Sciences
Yunnan Cancer Hospital
The First Affiliated Hospital of University of Science and Technology of China
Third Military Medical University
Liaoning Tumor Hospital & Institute
China Medical University
Tianjin Medical University
Sun Yat-Sen University Cancer Center
Shandong Cancer Hospital
Xi'an International Medical Center Hospital
Sun Yat-Sen University
Harbin Medical University
Beijing Hospital
Qinghai University

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.

Original language	English
Pages (from-to)	266-272
Number of pages	7
Journal	Journal of the National Cancer Center
Volume	3
Issue number	4
DOIs	https://doi.org/10.1016/j.jncc.2023.09.002
State	Published - Dec 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antibody-drug conjugate
Breast cancer
HER2-low

Access to Document

10.1016/j.jncc.2023.09.002

Cite this

Hong, B., Ying, F., Zhaoqing, F., Xichun, H., Man, L., Qiao, L., Ning, L., Ting, L., Jianyun, N., Yueyin, P., Xiaowei, Q., Zhimin, S., Guohong, S., Tao, S., Yue-e, T., Zhongsheng, T., Jiayu, W., Shusen, W., Xue, W., ... Jiuda, Z. (2023). Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition). Journal of the National Cancer Center, 3(4), 266-272. https://doi.org/10.1016/j.jncc.2023.09.002

@article{875b02a3d7a34b2b8b4f3fabe31fbb29,

title = "Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)",

abstract = "Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.",

keywords = "Antibody-drug conjugate, Breast cancer, HER2-low",

author = "Bu Hong and Fan Ying and Fan Zhaoqing and Hu Xichun and Li Man and Li Qiao and Liao Ning and Luo Ting and Nie Jianyun and Pan Yueyin and Qi Xiaowei and Shao Zhimin and Song Guohong and Sun Tao and Teng Yue-e and Tong Zhongsheng and Wang Jiayu and Wang Shusen and Wang Xue and Wang Yongsheng and Wang Zhonghua and Xu Binghe and Xu Ling and Xue Yan and Yang Wentao and Yao Herui and Ying Jianming and Yuan Peng and Zhang Jian and Zhang Qingyuan and Zhang Yongqiang and Zhao Jiuda",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = dec,

doi = "10.1016/j.jncc.2023.09.002",

language = "英语",

volume = "3",

pages = "266--272",

journal = "Journal of the National Cancer Center",

issn = "2096-8663",

publisher = "Chinese National Cancer Center",

number = "4",

}

Hong, B, Ying, F, Zhaoqing, F, Xichun, H, Man, L, Qiao, L, Ning, L, Ting, L, Jianyun, N, Yueyin, P, Xiaowei, Q, Zhimin, S, Guohong, S, Tao, S, Yue-e, T, Zhongsheng, T, Jiayu, W, Shusen, W, Xue, W, Yongsheng, W, Zhonghua, W, Binghe, X, Ling, X, Yan, X, Wentao, Y, Herui, Y, Jianming, Y, Peng, Y, Jian, Z, Qingyuan, Z, Yongqiang, Z & Jiuda, Z 2023, 'Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)', Journal of the National Cancer Center, vol. 3, no. 4, pp. 266-272. https://doi.org/10.1016/j.jncc.2023.09.002

TY - JOUR

T1 - Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)

AU - Hong, Bu

AU - Ying, Fan

AU - Zhaoqing, Fan

AU - Xichun, Hu

AU - Man, Li

AU - Qiao, Li

AU - Ning, Liao

AU - Ting, Luo

AU - Jianyun, Nie

AU - Yueyin, Pan

AU - Xiaowei, Qi

AU - Zhimin, Shao

AU - Guohong, Song

AU - Tao, Sun

AU - Yue-e, Teng

AU - Zhongsheng, Tong

AU - Jiayu, Wang

AU - Shusen, Wang

AU - Xue, Wang

AU - Yongsheng, Wang

AU - Zhonghua, Wang

AU - Binghe, Xu

AU - Ling, Xu

AU - Yan, Xue

AU - Wentao, Yang

AU - Herui, Yao

AU - Jianming, Ying

AU - Peng, Yuan

AU - Jian, Zhang

AU - Qingyuan, Zhang

AU - Yongqiang, Zhang

AU - Jiuda, Zhao

PY - 2023/12

Y1 - 2023/12

N2 - Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.

AB - Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1+, or IHC2+/in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The current consensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.

KW - Antibody-drug conjugate

KW - Breast cancer

KW - HER2-low

UR - https://www.scopus.com/pages/publications/85173988587

U2 - 10.1016/j.jncc.2023.09.002

DO - 10.1016/j.jncc.2023.09.002

M3 - 文章

AN - SCOPUS:85173988587

SN - 2096-8663

VL - 3

SP - 266

EP - 272

JO - Journal of the National Cancer Center

JF - Journal of the National Cancer Center

IS - 4

ER -

Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this